Inventiva (IVEVF) Cash & Equivalents (2018 - 2025)
Inventiva (IVEVF) posted Cash & Equivalents of $115.6 million for Q4 2025, down 16.34% on a QoQ basis from $138.2 million in Q2 2025, and up 12.03% year-over-year from $103.2 million in Q4 2024.
Analysis
Inventiva (IVEVF) Cash & Equivalents (2018 - 2025) Analysis & Trends
Inventiva has reported Cash & Equivalents for 8 years, with the latest figure at $115.6 million in Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 12.03% year-over-year to $115.6 million in Q4 2025; TTM through Dec 2025 was $115.6 million, a 12.03% increase from a year earlier, with the FY2025 full-year figure at $115.6 million, up 12.03% from the prior year.
- Cash & Equivalents was $115.6 million for Q4 2025 at Inventiva, down from $138.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $138.2 million in Q2 2025, with the low at $10.9 million in Q2 2024.
- Average Cash & Equivalents over 5 years is $85.7 million, with a median of $99.0 million recorded in 2021.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 67.88% in 2024, then soared 1164.6% in 2025.
- Over 5 years, Cash & Equivalents stood at $99.0 million in 2021, then retreated by 10.63% to $88.5 million in 2022, then plunged by 67.27% to $29.0 million in 2023, then surged by 256.29% to $103.2 million in 2024, then advanced by 12.03% to $115.6 million in 2025.
- The last three Cash & Equivalents figures came in at $115.6 million (Q4 2025), $138.2 million (Q2 2025), and $103.2 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 976.00 Mn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | 815.44 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 3.98 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 1.80 Bn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | 115.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 115.60 Mn |
| Jun 30, 2025 | 138.19 Mn |
| Dec 31, 2024 | 103.19 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Dec 31, 2023 | 28.96 Mn |
| Jun 30, 2023 | 34.02 Mn |
| Dec 31, 2022 | 88.49 Mn |
| Jun 30, 2022 | 81.53 Mn |
| Dec 31, 2021 | 99.01 Mn |
| Jun 30, 2021 | 112.76 Mn |
| Mar 31, 2021 | 130.04 Mn |
| Dec 31, 2020 | 126.01 Mn |
| Jun 30, 2020 | 57.58 Mn |
| Dec 31, 2019 | 39.67 Mn |
| Dec 31, 2018 | 64.71 Mn |